LMB86 chemotherapy regimen
| Drug, dosage/d . | Day . |
|---|---|
| Cytoreductive phase, COP | |
| Vincristine, 2 mg | d1 |
| Cyclophosphamide, 300 mg/m2 | d1 |
| Prednisone, 60 mg/m2 | d1 to d7 |
| Induction | |
| COPADM 1 | |
| Vincristine, 2 mg | d1 |
| Methotrexate, 8 g/m2 | d1 |
| Cyclophosphamide, 500 mg/m2 | d2 to d4 |
| Adriamycin, 60 mg/m2 | d2 |
| Prednisone, 60 mg/m2 | d1 to d7 |
| COPADM 2 | |
| Idem with vincristine, 2 mg | d1, d6 |
| Cyclophosphamide, 1000 mg/m2 | d2 to d4 |
| Prednisone, 60 mg/m2 | d1 to d7 |
| Consolidation, CYVE, ×2 | |
| Etoposide, 200 mg/m2 | d2 to d5 |
| ARA-C, 3 g/m2 | d2 to d5 |
| ARA-C, 50 mg/m2 | d1 to d4* |
| Drug, dosage/d . | Day . |
|---|---|
| Cytoreductive phase, COP | |
| Vincristine, 2 mg | d1 |
| Cyclophosphamide, 300 mg/m2 | d1 |
| Prednisone, 60 mg/m2 | d1 to d7 |
| Induction | |
| COPADM 1 | |
| Vincristine, 2 mg | d1 |
| Methotrexate, 8 g/m2 | d1 |
| Cyclophosphamide, 500 mg/m2 | d2 to d4 |
| Adriamycin, 60 mg/m2 | d2 |
| Prednisone, 60 mg/m2 | d1 to d7 |
| COPADM 2 | |
| Idem with vincristine, 2 mg | d1, d6 |
| Cyclophosphamide, 1000 mg/m2 | d2 to d4 |
| Prednisone, 60 mg/m2 | d1 to d7 |
| Consolidation, CYVE, ×2 | |
| Etoposide, 200 mg/m2 | d2 to d5 |
| ARA-C, 3 g/m2 | d2 to d5 |
| ARA-C, 50 mg/m2 | d1 to d4* |
MTX infusion was followed at hour 24 by folinic acid rescue (50 mg every 6 hours × 3 days). Maintenance therapy consisted of 4 sequences: (1) vincristine 2 mg d1, methotrexate 8 g/m2 d1, cyclophosphamide 500 mg/m2 d2-d3, adriamycin 60 mg/m2 d3, prednisone 60 mg/m2 d1- d5; (2) etoposide 150 mg/m2 d1-d3, ARA-C 100 mg/m2 SC d1-d5; (3) same as sequence no. 1 but without high-dose MTX; and (4) same as sequence no. 2. Intrathecal injection: MTX + ARA-C + HDR d1, d3, and d5 of COP; d2, d4, and d6 of COPADM 1 and COPADM 2; d2 of sequence 1.
Twelve-hour infusion before high-dose ARA-C.